PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 
Enaltus

Press Release


Receive press releases from Enaltus: By Email RSS Feeds:

Enaltus LLC (a HealthEdge Portfolio Company) Acquires ScarAway Brand


Enaltus, LLC (“Enaltus”) recently acquired the assets of Mitchell-Vance Laboratories, d/b/a ScarAway®.

Suwannee, GA, April 05, 2013 --(PR.com)-- Enaltus, LLC (“Enaltus”) recently acquired the assets of Mitchell-Vance Laboratories, d/b/a ScarAway®.

Founded in 2008 in Guilford, Connecticut, ScarAway is a line of OTC, professional grade, topical silicone scar treatments sold nation-wide through more than 20,000 retail stores. The ScarAway brand is an FDA-regulated medical device that utilizes clinically proven silicone technology and innovative treatment modalities to help flatten, soften, smooth, fade or improve the size and appearance of scars, particularly keloid and hypertrophic (raised) scars resulting from surgery, injuries, burns or acne. The ScarAway line consists of 100% silicone sheets and serum that can be used on any part of the body including the face, ears, neck, scalp, arms, hands and joint areas.

Enaltus is a Suwannee, Georgia-based business with U.S. and international presence that is primarily focused on developing, marketing and selling skincare products to physicians and direct to consumers via national and independent retailers. The Company’s flagship products, Kelo-cote® and bioCorneum®, are patented, self-drying, silicone gels and sprays used for scar treatment and prevention. Enaltus is a portfolio company of HealthEdge Investment Fund, L.P. (“HealthEdge”) a Tampa, Florida-based private equity fund focused exclusively on healthcare.

“Enaltus has become a leading provider in the professional and retail scar management category across the US and a significant player in the specialty skincare market through strong organic growth of its core brands, licensing of new brands and strategic acquisitions including Belli Skincare, a leader in skincare solutions for pre and post natal women and infants, in 2009 and now ScarAway” commented Jeff Thompson, CEO of Enaltus and Partner with HealthEdge.

Jessica Rowen, President of Mitchell-Vance Laboratories added, “We are very excited about the acquisition of ScarAway by Enaltus, and believe the combined portfolio of brands will gain additional distribution and benefit from similar, but different experiences in the scar management category. The combination of the ScarAway and Kelo-cote brands will enhance our capability to provide customers with best in class professional-grade scar treatment solutions.”

About Enaltus

Enaltus is a dermatological products company focused on scar management and specialty skincare. The company’s flagship products are Kelo-cote®, a patented, fast drying silicone gel and spray and Belli, a physician-formulated skincare line for pre and post-natal women and infants. Enaltus is headquartered in Suwannee, GA.

About HealthEdge

HealthEdge Investment Partners, LLC is an operating-oriented private equity firm founded in 2005 that focuses exclusively on investments in the healthcare industry. HealthEdge seeks to achieve superior returns by investing in businesses that benefit from the knowledge, experience, and network of relationships of its partners. HealthEdge partners have more than 100 years of combined experience in healthcare as CEOs and investors. For more information on HealthEdge, visit www.healthedgepartners.com.

For more information, please contact Jeff Thompson at Enaltus, LLC at (770) 329-8766.
Contact Information
Enaltus
Amber Clapp
646 567 8114
Contact

Click here to view the list of recent Press Releases from Enaltus
Promote Your Business